For­mer Al­lo­gene CFO Er­ic Schmidt talks about his new role at Can­tor and the fu­ture of cell ther­a­pies

Can­tor Fitzger­ald an­nounced on Tues­day that Er­ic Schmidt and Josh Schim­mer are join­ing its biotech re­search group.

Schim­mer is a for­mer se­nior man­ag­ing di­rec­tor of Ever­core ISI’s biotech re­search team, while Schmidt was most re­cent­ly the chief fi­nan­cial of­fi­cer at cell ther­a­py com­pa­ny Al­lo­gene. Pri­or to Al­lo­gene, Schmidt spent 20 years as an an­a­lyst at Cowen.

End­points chat­ted briefly over Zoom with Schmidt about Can­tor’s biotech eq­ui­ty re­search and the fu­ture of cell and gene ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER